Drug Monograph
Ruxolitinib (Topical)
ruxolitinib cream 1.5% — Opzelura
Pharmacokinetic Profile
Systemic Half-Life
~3 h (oral data); topical absorption results in measurable plasma levels
Metabolism
Hepatic (CYP3A4 primary; CYP2C9 minor)
Protein Binding
~97%
Topical Absorption
Measurable; plasma levels quantifiable in all subjects but well below systemic JAK-inhibitory threshold
Excretion
Urine 74%; faeces 22%
Clinical Information
Drug Class
Topical Janus Kinase (JAK1/JAK2) Inhibitor
Available Strength
1.5% cream (15 mg/g); 60 g and 100 g tubes
Route
Topical (dermatologic only)
Renal Adjustment
Not specified (limited systemic exposure)
Hepatic Adjustment
Not specified (limited systemic exposure)
Pregnancy
Insufficient human data; animal studies show fetal risk at high doses. Pregnancy registry available
Lactation
Advise not to breastfeed during treatment and for ~4 weeks after last dose
Schedule
Prescription only (Rx)
Black Box Warning
Yes — 5 components: serious infections, mortality, malignancy, MACE, thrombosis
Generic Available
No (brand only)
Ruxolitinib Topical — Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Mild-to-moderate atopic dermatitis | Non-immunocompromised adults and children ≥2 years | Short-term / non-continuous; second-line | FDA Approved (Sept 2021; ≥2y expanded Sept 2025) |
| Nonsegmental vitiligo | Adults and children ≥12 years | Continuous topical monotherapy | FDA Approved (July 2022) |
Ruxolitinib cream (Opzelura) is the first and only topical JAK inhibitor approved in the United States. It is a selective JAK1/JAK2 inhibitor indicated for two distinct dermatologic conditions. For atopic dermatitis, it is approved for mild-to-moderate disease in non-immunocompromised patients as second-line therapy when topical prescription therapies are inadequate or inadvisable. For nonsegmental vitiligo, it is the first FDA-approved pharmacological treatment for repigmentation. The use of ruxolitinib cream in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants (azathioprine, ciclosporin) is not recommended.
Dosing
Atopic Dermatitis
| Population | Application | BSA Limit | Maximum Use | Notes |
|---|---|---|---|---|
| Adults and children ≥12 years | 1.5% cream BID to affected areas | Up to 20% BSA | 60 g/week or 100 g/2 weeks | Stop when symptoms resolve. Re-examine if no improvement within 8 weeks. Do not use with occlusive dressings |
| Children 2–11 years | 1.5% cream BID to affected areas | Up to 20% BSA | 60 g/2 weeks | Lower maximum quantity than adults/adolescents. Same efficacy endpoints as older patients (TRuE-AD3) 1 patient handprint ≈ 1% BSA |
Nonsegmental Vitiligo
| Population | Application | BSA Limit | Maximum Use | Notes |
|---|---|---|---|---|
| Adults and children ≥12 years | 1.5% cream BID to affected areas | Up to 10% BSA | 60 g/week or 100 g/2 weeks | Repigmentation is slow; may require >24 weeks. Re-evaluate at 24 weeks if no meaningful response. Continuous treatment is appropriate for vitiligo (unlike AD) |
Clinical Pearl — Key Differences from Topical Calcineurin Inhibitors
Unlike TCIs (tacrolimus, pimecrolimus), ruxolitinib cream carries a more extensive boxed warning covering five JAK-class risks (serious infections, mortality, malignancy, MACE, and thrombosis) compared to the TCI malignancy-only warning. However, ruxolitinib has a dual indication (AD + vitiligo), has notably low application-site burning (<1% in AD vs up to 58% with tacrolimus), and is the only FDA-approved pharmacological treatment for vitiligo repigmentation. Ruxolitinib is also positioned at the same therapy line as TCIs (second-line after topical corticosteroids) per the VA formulary assessment.
Pharmacology
Mechanism of Action
Ruxolitinib is a selective inhibitor of Janus kinase 1 (JAK1) and JAK2, members of the JAK family of protein tyrosine kinases. These kinases mediate signalling of multiple cytokines and growth factors that are central to the pathogenesis of atopic dermatitis and vitiligo. In AD, overactivation of the JAK-STAT pathway drives Th2-mediated inflammation and pruritus via cytokines including IL-4, IL-13, IL-31, and TSLP. In vitiligo, interferon-γ (IFN-γ) signalling through the JAK1/JAK2-STAT1 pathway drives autoimmune melanocyte destruction via CXCL9/CXCL10 chemokine production. By inhibiting JAK1/JAK2, ruxolitinib blocks phosphorylation of STATs and reduces downstream pro-inflammatory gene transcription. Unlike calcineurin inhibitors (which primarily target T-cell activation), ruxolitinib broadly modulates cytokine signalling through multiple immune cell types.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Topical absorption results in quantifiable plasma levels in all subjects; adult mean Cmax 449 ± 883 nM on Day 1; pediatric (2–11 y) mean Css ~29.7–76.5 nM at 1.5%; levels well below the 281 nM threshold associated with systemic JAK inhibition | Meaningful systemic JAK inhibition is considered highly unlikely at these levels; however, unlike TCIs, plasma levels are consistently detectable, supporting the need for the JAK class boxed warning |
| Distribution | ~97% plasma protein-bound | Moderate protein binding; lower than TCIs (~99%+) |
| Metabolism | Hepatic via CYP3A4 (primary) and CYP2C9 (minor); strong CYP3A4 inhibitors increase oral ruxolitinib Cmax by 33% and AUC by 91% (ketoconazole interaction study) | Avoid concomitant use with strong CYP3A4 inhibitors; clinically relevant for patients with extensive application areas or compromised skin barrier |
| Elimination | Urine ~74%; faeces ~22%; oral elimination t½ ~3 h | The 4-week post-treatment breastfeeding restriction suggests a longer effective half-life with topical depot absorption compared with the 3-hour oral half-life |
Side Effects
Adverse event data are from three pivotal phase 3 AD trials (TRuE-AD1, TRuE-AD2: adults/adolescents ≥12y, N=499 ruxolitinib vs N=250 vehicle, 8 weeks; TRuE-AD3: children 2–11y, N=130 vs N=65) and two phase 3 vitiligo trials (TRuE-V1, TRuE-V2: ≥12y, N=449 vs N=224, 24 weeks), as reported in the FDA PI (September 2025 revision).
Atopic Dermatitis — Adults & Adolescents (≥12 years)
≥1%
Common (≥1% and Greater Than Vehicle)
| Adverse Reaction | Ruxolitinib (N=499) | Vehicle (N=250) |
|---|---|---|
| Nasopharyngitis | 3% | 1% |
| Bronchitis | 1% | 0% |
| Ear infection | 1% | 0% |
| Eosinophil count increased | 1% | 0% |
| Urticaria | 1% | 0% |
| Diarrhoea | 1% | <1% |
| Folliculitis | 1% | 0% |
| Tonsillitis | 1% | 0% |
| Rhinorrhoea | 1% | <1% |
Additional AEs occurring in <1% of ruxolitinib subjects and 0% vehicle: neutropenia, allergic conjunctivitis, pyrexia, seasonal allergy, herpes zoster, otitis externa, staphylococcal infection, acneiform dermatitis. Application-site burning was notably more common with vehicle (4.4%) than ruxolitinib 1.5% (0.8%).
Atopic Dermatitis — Children (2–11 years)
≥1%
Common (≥1% and Greater Than Vehicle; TRuE-AD3)
| Adverse Reaction | Ruxolitinib (N=130) | Vehicle (N=65) |
|---|---|---|
| Upper respiratory tract infection (includes nasopharyngitis, rhinorrhoea, oropharyngeal pain, respiratory congestion, viral URI) | 15% | 11% |
| COVID-19 | 5% | 3% |
| Application site reaction (pain, irritation, discomfort, pruritus) | 5% | 2% |
| Pyrexia | 2% | 0% |
| White blood cell decreased (includes leukopenia) | 2% | 0% |
Nonsegmental Vitiligo (≥12 years)
≥1%
Common (≥1% and ≥1% Greater Than Vehicle; TRuE-V1/V2, 24 weeks)
| Adverse Reaction | Ruxolitinib (N=449) | Vehicle (N=224) |
|---|---|---|
| Application site acne | 6% | 1% |
| Application site pruritus | 5% | 3% |
| Nasopharyngitis | 4% | 2% |
| Headache | 4% | 3% |
| Urinary tract infection | 2% | <1% |
| Application site erythema | 2% | <1% |
| Pyrexia | 1% | 0% |
Boxed Warning
JAK-Class Serious Adverse Events (from Oral JAK Inhibitor Data)
| Risk Category | Details | Management |
|---|---|---|
| Serious infections | TB, invasive fungal, bacterial, viral, opportunistic. Serious lower respiratory infections reported in the topical development programme. No active TB in topical trials. | Evaluate for latent/active TB before starting. Monitor for infection signs. Interrupt treatment if serious infection develops. |
| Mortality | Higher all-cause mortality (including sudden CV death) observed with oral JAK inhibitors vs TNF blockers in the RA ORAL Surveillance study. | Weigh benefits vs risks. Counsel patients on cardiovascular warning signs. |
| Malignancy | Lymphoma, other malignancies, NMSC reported. Current/past smokers at additional risk. NMSC (BCC, SCC) reported with Opzelura specifically. | Periodic skin examinations. Limit UV exposure; protective clothing and sunscreen. Consider risk in current/past smokers. |
| MACE | CV death, MI, stroke. Higher rates seen with oral JAK inhibitors vs TNF blockers in RA patients ≥50 y with CV risk factors. | Discontinue if MI or stroke occurs. Consider CV risk factors before initiation. |
| Thrombosis | DVT, PE, arterial thrombosis. Thromboembolic events observed in topical ruxolitinib trials. | Avoid in patients at high thrombosis risk. Discontinue if thrombosis symptoms occur. |
Discontinuation
Discontinuation Rates (TRuE-AD1/AD2, 8-week VC period)
Ruxolitinib 1.5% Cream
0.6% (3/499) discontinued due to TEAEs
Context: Lower discontinuation rate than vehicle (3.2%, 8/250). No treatment-related serious TEAEs. Most common treatment-related AE was application-site burning, which was more frequent with vehicle (4.4%) than ruxolitinib 1.5% (0.8%).
Drug Interactions
Drug interaction studies with topical Opzelura have not been conducted. Ruxolitinib is a known CYP3A4 substrate; interactions are extrapolated from oral ruxolitinib (Jakafi) data.
Major
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat)
MechanismInhibition of CYP3A4-mediated ruxolitinib metabolism
EffectOral data: ketoconazole increased ruxolitinib Cmax by 33% and AUC by 91%
ManagementAvoid concomitant use per FDA PI. Potential to increase systemic exposure and risk of adverse reactions.
FDA PI Section 7
Major
Other JAK inhibitors, therapeutic biologics, potent immunosuppressants (azathioprine, ciclosporin)
MechanismAdditive immunosuppression; overlapping mechanism
EffectIncreased risk of serious infections, malignancy, and other immune-mediated adverse events
ManagementNot recommended per FDA PI Limitation of Use. Do not combine with dupilumab, tralokinumab, upadacitinib, abrocitinib, or other JAK inhibitors.
FDA PI Section 1.3
Moderate
CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John’s Wort)
MechanismIncreased CYP3A4-mediated metabolism of ruxolitinib
EffectDecreased ruxolitinib systemic concentrations; potential reduction in efficacy
ManagementMonitor for reduced treatment response; clinical significance with topical route is uncertain
FDA PI Section 7
Minor
Live vaccines
MechanismTheoretical concern for impaired vaccine immune response due to JAK inhibition
EffectNot specifically studied with topical ruxolitinib; clinical significance uncertain given low systemic exposure
ManagementEnsure vaccination schedule is up to date before initiating; consider herpes zoster vaccination per FDA PI recommendation
FDA PI Section 5.1Monitoring
-
Complete Blood Count (CBC)
As clinically indicated
Routine Thrombocytopenia, anaemia, neutropenia, lymphopenia, and leucopenia reported in clinical trials. WBC decrease occurred in 2% of pediatric subjects (2–11 y). Discontinue if clinically significant decreases occur. Subjects with Hb <10 g/dL, ANC <1000/μL, or platelets <100,000/μL were excluded from trials. -
Clinical Response
8-week review (AD); 24-week review (vitiligo)
Routine AD: if no improvement within 8 weeks, re-examine and confirm the diagnosis. Vitiligo: if no meaningful repigmentation by 24 weeks, re-evaluate therapy (FDA PI). -
Infection Surveillance
Ongoing
Trigger-Based Monitor for signs/symptoms of serious infections (bacterial, viral, fungal, mycobacterial). Interrupt Opzelura if serious infection develops. Consider latent/active TB evaluation before starting and monitor during treatment. -
Skin Examination
Periodic
Routine NMSC (BCC, SCC) reported with Opzelura. Perform periodic skin examinations during and after treatment. Advise sun protection (protective clothing, broad-spectrum sunscreen). -
Lipid Parameters
Consider baseline and periodic
Routine Oral ruxolitinib is associated with increased total cholesterol, LDL cholesterol, and triglycerides. Monitor lipids as clinically indicated. -
Cardiovascular & Thrombotic Events
Ongoing
Trigger-Based Educate patients on warning signs of MI, stroke, DVT, and PE. Discontinue if MI, stroke, or thrombosis occurs. Higher risk in patients ≥50 with CV risk factors (from oral JAK data).
Contraindications & Cautions
Absolute Contraindications
- None listed in the FDA prescribing information.
Relative Contraindications (Risk-Benefit Assessment Required)
- Active serious infection (including localised infections) — avoid use until infection is controlled.
- Active hepatitis B or C — initiation not recommended; HBV reactivation reported with oral ruxolitinib.
- History of or current malignancy (other than successfully treated NMSC) — weigh risks carefully; current/past smokers at additional risk.
- Increased thrombosis risk — avoid in patients at elevated risk of DVT, PE, or arterial thrombosis.
- Clinically significant cytopenias — patients with Hb <10 g/dL, ANC <1000/μL, or platelets <100,000/μL were excluded from trials.
- Immunocompromised patients — safety and efficacy not studied; not indicated for immunocompromised patients (AD indication).
- Children <2 years (AD) or <12 years (vitiligo) — safety and efficacy not established.
Use with Caution
- Pregnancy — insufficient human data; animal studies showed reduced fetal weight at 22× MRHD in rats and 0.7× MRHD in rabbits. Pregnancy exposure registry available (1-855-463-3463).
- Lactation — ruxolitinib detected in rat milk. Advise not to breastfeed during treatment and for approximately 4 weeks after last dose (~5–6 elimination half-lives).
- Concomitant strong CYP3A4 inhibitors — avoid combination (FDA PI).
FDA Boxed Warning — Five Components
JAK Inhibitor Class Warning for Serious Infections, Mortality, Malignancy, MACE, and Thrombosis
This is the most extensive boxed warning among topical dermatologic agents. Based on the ORAL Surveillance study of oral tofacitinib in RA patients ≥50 years with ≥1 CV risk factor, oral JAK inhibitors showed higher rates of serious infections, mortality, malignancy, MACE, and thrombosis compared to TNF blockers. While topical ruxolitinib produces much lower systemic exposure than oral dosing, the FDA applies the JAK-class warning to all ruxolitinib formulations. In topical AD trials (TRuE-AD1/AD2/AD3), no serious infections, MACE, malignancies, or thromboses were reported during the vehicle-controlled periods. In the long-term vitiligo safety analysis (867.9 patient-years of ruxolitinib exposure), no serious treatment-related TEAEs were reported.
Patient Counselling
Purpose of Therapy
Opzelura is a steroid-free prescription cream that works differently from other eczema or vitiligo treatments. For eczema, it reduces itch and inflammation by blocking specific immune pathways (JAK1/JAK2). For vitiligo, it is the first approved treatment that can help restore skin colour by reducing the autoimmune attack on pigment-producing cells. It comes with important safety information that requires a Medication Guide with each prescription.
How to Apply
Tell patient
Apply a thin layer to affected skin areas only, twice a day. For eczema, use on up to 20% of body (about 20 handprints). For vitiligo, use on up to 10% of body. Do not cover with bandages. Do not apply to eyes, mouth, or genitals. Wash hands after application unless hands are being treated. For eczema, stop when symptoms clear. For vitiligo, continue treatment as repigmentation is gradual.
Quantity Limits
Tell patient
Adults and children ≥12: do not use more than one 60 g tube per week. Children 2–11 (eczema only): do not use more than one 60 g tube every 2 weeks. Using more cream than recommended may increase absorption and side-effect risk.
Infection Signs
Tell patient
This medication may increase infection risk. Contact your prescriber immediately if you develop: fever, chills, or flu-like symptoms; persistent cough or shortness of breath; painful skin blisters (shingles); or any infection that does not improve.
Cardiovascular & Blood Clot Warning
Tell patient
Seek emergency care if you experience chest pain, sudden shortness of breath, leg swelling or pain, sudden numbness or weakness (especially on one side), or sudden vision changes. These may indicate a heart attack, stroke, or blood clot.
Skin Cancer & Sun Protection
Tell patient
Limit sun exposure. Wear protective clothing and use broad-spectrum sunscreen. Report any new or changing skin growths, non-healing sores, or unusual moles to your prescriber promptly.
Pregnancy & Breastfeeding
Tell patient
Tell your prescriber if you are pregnant, planning pregnancy, or breastfeeding. Do not breastfeed during treatment or for about 4 weeks after your last dose. A pregnancy registry is available; report exposure by calling 1-855-463-3463.
Sources
Regulatory (PI / SmPC)
- OPZELURA (ruxolitinib) cream, 1.5% — FDA Prescribing Information (September 2025 revision). accessdata.fda.gov Current FDA label with full adverse event data from TRuE-AD1/2/3 and TRuE-V1/2, PK data, boxed warning text, dosing for both indications including the 2025 paediatric expansion to ≥2 years.
- OPZELURA (ruxolitinib) cream, 1.5% — FDA Prescribing Information (2022 revision with vitiligo indication). accessdata.fda.gov Earlier FDA label with original AD and vitiligo adverse event tables, boxed warning for ≥12 years population.
- NDA 215309/S-007 Multi-disciplinary Review and Evaluation — FDA. fda.gov Paediatric expansion review document with TRuE-AD3 trial evaluation, PK data in children 2–11 years, and approval rationale for the 2025 labelling update.
Key Clinical Trials — Atopic Dermatitis
- Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863–872. doi:10.1016/j.jaad.2021.04.085 Pivotal TRuE-AD1/AD2 publications (N>1,200, ≥12 y). Primary source for 8-week AE data, IGA treatment success, and EASI-75 endpoints in adults and adolescents.
- Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88(5):1008–1016. doi:10.1016/j.jaad.2022.09.060 44-week long-term extension data from TRuE-AD1/AD2 demonstrating effective as-needed disease control and sustained safety; patients spent median 38–44% of the LTS period off treatment due to clearance.
- Eichenfield LF, Stein Gold LF, Simpson EL, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study. J Am Acad Dermatol. 2025;93(3):689–698. doi:10.1016/j.jaad.2025.05.1385 Paediatric pivotal trial (N=330, ages 2–11). IGA-TS achieved by 56.5% (1.5% cream) vs 10.8% (vehicle) at Week 8. Basis for the 2025 age expansion to ≥2 years.
Key Clinical Trials — Vitiligo
- Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445–1455. doi:10.1056/NEJMoa2118828 Landmark TRuE-V1/V2 publication (N=674, ≥12 y). F-VASI75 at 24 weeks: 29.8% (TRuE-V1) and 30.9% (TRuE-V2) vs 7.4%/11.4% vehicle. Continued improvement through 52 weeks.
- Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110–120. doi:10.1016/S0140-6736(20)30609-7 Phase 2 dose-ranging study establishing the 1.5% BID dose for vitiligo; 45% achieved F-VASI50 at 24 weeks, 30% achieved F-VASI75 at 52 weeks.
Guidelines / Reviews
- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi:10.1016/j.jaad.2014.03.023 AAD guideline establishing the stepwise approach to topical AD therapy; pre-dates ruxolitinib approval but provides the framework for second-line positioning.
- Ruxolitinib (OPZELURA) Cream for Atopic Dermatitis — National Drug Monograph, VA Pharmacy Benefits Management Services. August 2022. va.gov VA formulary assessment placing topical ruxolitinib at the same therapy line as TCIs (second-line); notes more extensive boxed warnings than crisaborole or TCIs.
Safety / Mechanistic
- Eichenfield LF, Simpson EL, Papp K, et al. Efficacy, safety, and long-term disease control of ruxolitinib cream among adolescents with atopic dermatitis: pooled results from two randomized phase 3 studies. Am J Clin Dermatol. 2024;25(4):669–683. doi:10.1007/s40257-024-00855-2 Adolescent subgroup analysis (12–17 y) from TRuE-AD1/AD2 through 52 weeks; no serious infections, malignancies, MACE, or thromboembolic events.
- Ruxolitinib (Opzelura). CADTH Reimbursement Review. NCBI Bookshelf. ncbi.nlm.nih.gov/books/NBK616193 Canadian health technology assessment with independent evaluation of TRuE-AD trial evidence, cost-effectiveness analysis, and identified limitations.
- Zhang L, Du D, Wang L, et al. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: a network meta-analysis. J Dermatol. 2021;48(12):1880–1888. doi:10.1111/1346-8138.16126 Network meta-analysis comparing topical JAK inhibitors and PDE4 inhibitors for AD; provides comparative context for ruxolitinib efficacy.